Drug intelligence / Profile preview

AT-021

Development stage: Preclinical
Lead developer: Asieris Pharmaceuticals
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AT-021 is an antibody-drug conjugate (ADC) being developed by Asieris Pharmaceuticals for the treatment of breast cancer and other solid tumors. The drug is currently in preclinical development, with its primary indication being breast cancer. As an ADC, AT-021 combines a monoclonal antibody specific to a tumor-associated antigen with a cytotoxic agent, allowing targeted delivery of the cytotoxic payload to cancer cells while minimizing effects on normal tissues. This targeted approach aims to improve efficacy and reduce systemic toxicity compared to traditional chemotherapy[1][2].

Beyond the preview

Go deeper on AT-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-021.

Explore the full profile